-
Posted by
Two Blokes Jun 18 -
Filed in
Stock
-
5 views
Spyre Therapeutics, Inc.'s SPY002 and SPY072 drug candidates showed strong safety and TL1A inhibition in a phase 1 study, supporting advancement to phase 2 clinical development. SPY002 targets ulcerative colitis, while SPY072 will address multiple rheumatological conditions, with large market opportunities and key data readouts expected in 2025-2026. The extended half-life of these candidates could enable infrequent dosing, potentially offering a best-in-class advantage over competitors in the autoimmune and inflammatory disorders space.
